phase 1_completion
saveBristar Immunotech Biotechnology Co Ltd — YTS-109 (Phase I Trial Completion)
community read0 votes
Therapy area: Hematological Disorders, Immunology. Indication: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), Lupus Nephritis, Thrombocytopenia
Data sources
globaldata
Found something off?
comments(0)
5-min edit window · permanent after that